Drug
Blinatumomab
Blinatumomab: highest development phase Phase 2, developed by Amgen. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Blinatumomab NCT06054113 | Phase 2 | B Precursor Acute Lymphoblastic Leukemia |
| Blinatumomab NCT07134088 | Phase 1/2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia |
| Blinatumomab NCT01471782 | Phase 1/2 | Acute Lymphoblastic Leukemia |
Latest
No recent events.
Follow Blinatumomab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.